Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 11/20 | 0.43 |
| ▸ | AKR1A1 | P14550 | 10/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258212 | 0.90 | AR (0.53) | ARP2RX7PTGDR2 | |
| SCHEMBL4256761 | 0.82 | CHRM5 (0.53) | AKR1B1AKR1A1CHRM5PTGDR2 | |
| SCHEMBL4163964 | 0.82 | AKR1B1 (0.41) | AKR1B1AKR1A1CHRM5 | |
| SCHEMBL4260419 | 0.82 | PARK7 (0.51) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL4263802 | 0.80 | AKR1B1 (0.43) | AKR1B1AKR1A1CHRM5PTGDR2 | |
| SCHEMBL4255745 | 0.79 | AKR1B1 (0.47) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL4161594 | 0.79 | AKR1B1 (0.42) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL4262828 | 0.78 | AKR1B1 (0.46) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL4160449 | 0.78 | AKR1B1 (0.45) | AKR1B1AKR1A1CHRM5PTGDR2 | |
| SCHEMBL4168877 | 0.78 | SCN9A (0.44) | AKR1B1AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | claimed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV2, TRPV3 | AR 352/4885AKR1B1 366/4885AKR1A1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.